BenevolentAI: Revolutionizing Drug Discovery with AI

BenevolentAI (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, has been making waves in the biopharmaceutical industry with its innovative approach to identifying novel drug candidates. By harnessing the power of advanced AI and machine learning techniques, BenevolentAI's platform enables the company to analyze vast amounts of biomedical data, generating novel targets and pathways with a higher probability of clinical success.



BenevolentAI's platform offers several advantages over traditional drug discovery methods, including reduced costs, accelerated timelines, and improved success rates. The company's AI-driven approach has been validated through strategic collaborations with leading biopharmaceutical companies, such as AstraZeneca and Merck. These partnerships have resulted in the identification of multiple novel targets and the generation of high-potential clinical and preclinical assets.



AstraZeneca has identified multiple targets for its drug pipeline using BenevolentAI's platform, including three targets for idiopathic pulmonary fibrosis (IPF) and four targets for chronic kidney disease (CKD). AstraZeneca has selected these targets for portfolio entry, demonstrating the platform's ability to generate high-quality, clinically relevant targets. Professor Maria Belvisi, SVP and Head of Research and Early Development, Respiratory and Immunology at AstraZeneca, stated: "Our partnership with BenevolentAI furthers our commitment and we are proud to deliver a second novel target for IPF to our portfolio."

Merck has entered into a multi-year collaboration with BenevolentAI to identify and develop innovative compounds in oncology, neurology, and immunology. The collaboration involves the use of BenevolentAI's end-to-end AI platform capabilities to generate novel development candidates. Merck will receive low double-digit million US dollar upfront payments, discovery, development, regulatory, and commercial milestone payments, and tiered royalties based on net sales, further validating the platform's value.

Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck, stated: "The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner."

BenevolentAI's platform is driven by advanced AI and machine learning capabilities, a disease-agnostic and modality-agnostic approach, iterative learning and continuous improvement, collaborations with industry leaders, end-to-end drug discovery offerings, and a diverse team of scientists and technologists. These key factors contribute to the Company's long-term prospects, enabling BenevolentAI to accelerate drug discovery, improve the probability of clinical success, and deliver life-changing treatments to patients.

In conclusion, BenevolentAI's AI-driven drug discovery platform offers a compelling alternative to traditional methods, with the potential to revolutionize the biopharmaceutical industry. Through strategic collaborations and a focus on innovation, BenevolentAI is well-positioned to continue driving advancements in biopharmaceutical research and development, ultimately delivering life-changing treatments to patients.